Clinical trial studies safety and efficacy of combined immunotherapies with different mechanisms of action in advanced tumors


A new study for patients with advanced, inoperable or metastatic solid tumors combines two drugs that prompt the immune system in different ways. The immunotherapy drug avelumab blocks a signal that ordinarily stops the body’s immune system from attacking a tumor. In this way, avelumab takes the “brakes” off the immune system. In contrast, the drug NHS-IL12 acts like an “accelerator” for the immune system, stimulating it to be more active against cancer cells that have not responded to other treatments. James L. Gulley, M.D., Ph.D., is leading a team from the Genitourinary Malignancies Branch to see if the form of NHS-IL12 used in this study (M9241) that directly targets tumor cells may have less severe side effects than other forms of IL-12 in patients. For more information about this multi-center study, please visit: https://clinicaltrials.gov/ct2/show/NCT02994953

Summary Posted: 03/2017